Differential efatutazone’s impact on mammary neoplasia dependent upon Brca1 dose

Схожие документы

• The PPARγ Agonist Efatutazone Increases the Spectrum of Well-Differentiated Mammary Cancer Subtypes Initiated by Loss of Full-Length BRCA1 in Association with TP53 Haploinsufficiency
  по: Nakles, Rebecca E., et al.
  Опубликовано: (2013)
• Responsiveness of Brca1 and Trp53 deficiency induced mammary preneoplasia to selective estrogen modulators versus an aromatase inhibitor in Mus musculus
  по: Alothman, Sahar J., et al.
  Опубликовано: (2017)
• The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ
  по: Ory, Virginie, et al.
  Опубликовано: (2018)
• Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia
  по: Díaz-Cruz, Edgar S., et al.
  Опубликовано: (2010)
• Primary cancer cell culture: mammary-optimized versus conditional-reprogramming
  по: Alamri, Ahmad M., et al.
  Опубликовано: (2016)